Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma

Authors: White C.A.; Berlfein J.R.; Grillo-Lopez A.J.

Source: Current Pharmaceutical Biotechnology, Volume 1, Number 4, December 2000 , pp. 303-312(10)

Publisher: Bentham Science Publishers

Abstract:

The scientific development of immunotherapies and radioimmunotherapies of cancer began more than four decades ago. Over time, it has become apparent that the choice of target antigen, immunogenicity of antibodies, length of antibody half-life, ability of antibodies to recruit immune effector functions, decision on conjugation of antibodies to toxins or radionuclides and antibody manufacturing are critical components of successful development of an immunotherapeutic regimen. Anti-idiotype antibodies were some of the first successful monoclonal antibody treatments developed for non-Hodgkins lymphoma. In 1997, the chimeric antibody, Rituximab, was approved by the United States Food and Drug Administration for treatment of patients with relapsed or refractory low-grade or follicular non-Hodgkins lymphoma. In an effort to enhance the efficacy of immunotherapy, toxins and radionuclides have been conjugated to monoclonal antibodies. Ibritumomab, the parent murine antibody of Rituximab, is conjugated to the radioisotope 90Y to create 90Y Ibritumomab tiuxetan, (90Y Zevalin, IDEC-Y2B8). Promising Phase I/II trials have been completed. Phase III experimental trials of 90Y Ibritumomab tiuxetan as treatment for relapsed or refractory NHL are in progress.

Keywords: Non hodgkin; Immunotherapies; Toxins; Radionuclides; Lymphoma; Monoclonal antibodies; CEA; Radioimmunotherapies

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389201003378889

Publication date: 2000-12-01

• Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

• In this: publication
• By this: publisher
• In this Subject: Nutrition & Food ,  Biotechnology ,  Pharmacology
• By this author: White C.A. ;  Berlfein J.R. ;  Grillo-Lopez A.J.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers